BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 31583566)

  • 1. Development and verification of a three-dimensional (3D) breast cancer tumor model composed of circulating tumor cell (CTC) subsets.
    Anil-Inevi M; Sağlam-Metiner P; Kabak EC; Gulce-Iz S
    Mol Biol Rep; 2020 Jan; 47(1):97-109. PubMed ID: 31583566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epithelial-to-mesenchymal transition leads to loss of EpCAM and different physical properties in circulating tumor cells from metastatic breast cancer.
    Hyun KA; Koo GB; Han H; Sohn J; Choi W; Kim SI; Jung HI; Kim YS
    Oncotarget; 2016 Apr; 7(17):24677-87. PubMed ID: 27013581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoroughened adhesion-based capture of circulating tumor cells with heterogeneous expression and metastatic characteristics.
    Chen W; Allen SG; Reka AK; Qian W; Han S; Zhao J; Bao L; Keshamouni VG; Merajver SD; Fu J
    BMC Cancer; 2016 Aug; 16():614. PubMed ID: 27501846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The isolation and characterization of CTC subsets related to breast cancer dormancy.
    Vishnoi M; Peddibhotla S; Yin W; T Scamardo A; George GC; Hong DS; Marchetti D
    Sci Rep; 2015 Dec; 5():17533. PubMed ID: 26631983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance).
    Magbanua MJM; Rugo HS; Wolf DM; Hauranieh L; Roy R; Pendyala P; Sosa EV; Scott JH; Lee JS; Pitcher B; Hyslop T; Barry WT; Isakoff SJ; Dickler M; Van't Veer L; Park JW
    Clin Cancer Res; 2018 Mar; 24(6):1486-1499. PubMed ID: 29311117
    [No Abstract]   [Full Text] [Related]  

  • 6. c-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive/HER2-negative metastatic breast cancer.
    Park J; Chang ES; Kim JY; Chelakkot C; Sung M; Song JY; Jung K; Lee JH; Choi JY; Kim NY; Lee H; Kang MR; Kwon MJ; Shin YK; Park YH; Choi YL
    Breast Cancer Res; 2024 Jan; 26(1):13. PubMed ID: 38238761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolation of Breast cancer CTCs with multitargeted buoyant immunomicrobubbles.
    Wang G; Benasutti H; Jones JF; Shi G; Benchimol M; Pingle S; Kesari S; Yeh Y; Hsieh LE; Liu YT; Elias A; Simberg D
    Colloids Surf B Biointerfaces; 2018 Jan; 161():200-209. PubMed ID: 29080504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EpCAM-Independent Enrichment of Circulating Tumor Cells in Metastatic Breast Cancer.
    Schneck H; Gierke B; Uppenkamp F; Behrens B; Niederacher D; Stoecklein NH; Templin MF; Pawlak M; Fehm T; Neubauer H;
    PLoS One; 2015; 10(12):e0144535. PubMed ID: 26695635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EpCAM based capture detects and recovers circulating tumor cells from all subtypes of breast cancer except claudin-low.
    Ring A; Mineyev N; Zhu W; Park E; Lomas C; Punj V; Yu M; Barrak D; Forte V; Porras T; Tripathy D; Lang JE
    Oncotarget; 2015 Dec; 6(42):44623-34. PubMed ID: 26556851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A biosensor capable of identifying low quantities of breast cancer cells by electrical impedance spectroscopy.
    Huerta-Nuñez LFE; Gutierrez-Iglesias G; Martinez-Cuazitl A; Mata-Miranda MM; Alvarez-Jiménez VD; Sánchez-Monroy V; Golberg A; González-Díaz CA
    Sci Rep; 2019 Apr; 9(1):6419. PubMed ID: 31015522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of HER2 expression in urothelial carcinoma cells as a biomarker for circulating tumor cells.
    Nini A; Hoffmann MJ; Lampignano R; Große Siemer R; van Dalum G; Szarvas T; Cotarelo CL; Schulz WA; Niederacher D; Neubauer H; Stoecklein NH; Niegisch G
    Cytometry B Clin Cytom; 2020 Jul; 98(4):355-367. PubMed ID: 32212383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of circulating tumor cells during follow-up of patients with early breast cancer: Clinical utility for monitoring of therapy efficacy.
    Mikulová V; Cabiňaková M; Janatková I; Mestek O; Zima T; Tesařová P
    Scand J Clin Lab Invest; 2014 Mar; 74(2):132-42. PubMed ID: 24350991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy.
    Onstenk W; Kraan J; Mostert B; Timmermans MM; Charehbili A; Smit VT; Kroep JR; Nortier JW; van de Ven S; Heijns JB; Kessels LW; van Laarhoven HW; Bos MM; van de Velde CJ; Gratama JW; Sieuwerts AM; Martens JW; Foekens JA; Sleijfer S
    Mol Cancer Ther; 2015 Mar; 14(3):821-7. PubMed ID: 25552367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of different CTC subpopulations in non-small cell lung cancer.
    Hanssen A; Wagner J; Gorges TM; Taenzer A; Uzunoglu FG; Driemel C; Stoecklein NH; Knoefel WT; Angenendt S; Hauch S; Atanackovic D; Loges S; Riethdorf S; Pantel K; Wikman H
    Sci Rep; 2016 Jun; 6():28010. PubMed ID: 27302574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel method for downstream characterization of breast cancer circulating tumor cells following CellSearch isolation.
    Frithiof H; Welinder C; Larsson AM; Rydén L; Aaltonen K
    J Transl Med; 2015 Apr; 13():126. PubMed ID: 25896421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular biomarker analyses using circulating tumor cells.
    Punnoose EA; Atwal SK; Spoerke JM; Savage H; Pandita A; Yeh RF; Pirzkall A; Fine BM; Amler LC; Chen DS; Lackner MR
    PLoS One; 2010 Sep; 5(9):e12517. PubMed ID: 20838621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients.
    Königsberg R; Obermayr E; Bises G; Pfeiler G; Gneist M; Wrba F; de Santis M; Zeillinger R; Hudec M; Dittrich C
    Acta Oncol; 2011 Jun; 50(5):700-10. PubMed ID: 21261508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolation of breast cancer and gastric cancer circulating tumor cells by use of an anti HER2-based microfluidic device.
    Galletti G; Sung MS; Vahdat LT; Shah MA; Santana SM; Altavilla G; Kirby BJ; Giannakakou P
    Lab Chip; 2014 Jan; 14(1):147-56. PubMed ID: 24202699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen receptor expression on circulating tumor cells in metastatic breast cancer.
    Fujii T; Reuben JM; Huo L; Espinosa Fernandez JR; Gong Y; Krupa R; Suraneni MV; Graf RP; Lee J; Greene S; Rodriguez A; Dugan L; Louw J; Lim B; Barcenas CH; Marx AN; Tripathy D; Wang Y; Landers M; Dittamore R; Ueno NT
    PLoS One; 2017; 12(9):e0185231. PubMed ID: 28957377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients.
    Aktas B; Kasimir-Bauer S; Müller V; Janni W; Fehm T; Wallwiener D; Pantel K; Tewes M;
    BMC Cancer; 2016 Jul; 16():522. PubMed ID: 27456970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.